In the setting of HIV, HIV-1–specific IgG3 has been shown to be correlated with decreased risk of HIV-1 infection in human clinical trials,41 and IgG3 bnAbs have been found to exhibit improved binding to FcγRIIa which correlated with enhanced phagocytosis, and increased antibody-dependent cellular cytotoxicity.42 This evidence concerns the gene IGHG3 and HIV-1 infection.